SCHEMBL6502882

SCHEMBL6502882

CC(C)(C)OC(=O)Nc1cc(-c2cccc(N)c2)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.49
TGFBR1 P36897 1/20 0.46
CYP17A1 P05093 1/20 0.44
AAK1 Q2M2I8 10/20 0.43
GSK3B P49841 1/20 0.43
DYRK1A Q13627 1/20 0.43
EGFR P00533 1/20 0.43
MAP4K4 O95819 1/20 0.43
PIK3C3 Q8NEB9 4/20 0.43
CYP3A4 P08684 1/20 0.41
CIT O14578 1/20 0.41
DAPK3 O43293 1/20 0.41
JAK2 O60674 1/20 0.41
DAPK1 P53355 1/20 0.41
MAP2K1 Q02750 1/20 0.41
PKN2 Q16513 1/20 0.41
TLK2 Q86UE8 1/20 0.41
HIPK4 Q8NE63 1/20 0.41
MKNK1 Q9BUB5 1/20 0.41
MYLK2 Q9H1R3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5251219 0.87 EGFR (0.57) IRAK4TGFBR1CYP17A1AAK1GSK3B
SCHEMBL17643492 0.86 AAK1 (0.48) IRAK4TGFBR1AAK1GSK3BDYRK1A
SCHEMBL29992322 0.86 AAK1 (0.48) IRAK4TGFBR1AAK1GSK3BDYRK1A
SCHEMBL7909650 0.85 ATR (0.46) IRAK4TGFBR1CYP17A1AAK1GSK3B
SCHEMBL24004071 0.84 ACVRL1 (0.47) IRAK4TGFBR1CYP17A1JAK2
SCHEMBL13623044 0.83 IRAK4 (0.42) IRAK4TGFBR1CYP17A1GSK3BDYRK1A
SCHEMBL6501406 0.83 PIP5K1C (0.54) CYP17A1EGFR
SCHEMBL13623045 0.82 NR3C2 (0.54) IRAK4
SCHEMBL8670718 0.81 FDPS (0.50) IRAK4TGFBR1CYP17A1AAK1GSK3B
SCHEMBL13669973 0.81 CYP17A1 (0.47) IRAK4CYP17A1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005051381-A1 Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) BIOVITRUM AB (SE) 2005-06-09 WO claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2005003123-A1 NOVEL PYRIDINE DERIVATIVES AS JNK SPECIFIC INHIBITORS ASTRAZENECA AB (SE) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK IRAK4 34/4885TGFBR1 478/4885CYP17A1 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.